|
WO2021057906A1
|
|
Immune effector cell expressing il-15
|
|
WO2021052496A1
|
|
Immune effector cell in which expression is regulated by cytokines
|
|
WO2021027785A1
|
|
Immune effector cell for co-expressing chemokine receptor
|
|
WO2020259707A1
|
|
Cell for resisting transplant reaction and method
|
|
WO2020156554A1
|
|
Tcr fusion protein and cell expressing tcr fusion protein
|
|
WO2020143631A1
|
|
Cellular immunotherapy combination
|
|
WO2020114518A1
|
|
Tumor combined immunotherapy
|
|
WO2020083406A1
|
|
Cll1-targeting antibody and application thereof
|
|
WO2020063988A1
|
|
Combination therapy of cldn18 antibody and chemotherapy drugs
|
|
WO2020057666A1
|
|
T-cell expressing chimeric receptor
|
|
WO2020057641A1
|
|
Chemokine expressing cell and use thereof
|
|
CA3107515A1
|
|
Method for tumor treament with immune effector cells
|
|
KR20210018838A
|
|
Genetically engineered cells and applications
|
|
EP3789486A1
|
|
Immune effector cell and use thereof
|
|
WO2019170147A1
|
|
Method and composition for treating tumors
|
|
EP3747433A1
|
|
Combination of cellular immunotherapy
|
|
EP3741861A1
|
|
Synnotch receptor-regulated expression of il12
|
|
WO2020118634A1
|
|
Immune effector cell targeting gpc3 and application thereof
|
|
WO2019114762A1
|
|
Combined use of immune effector cells and radiation for treating tumours
|
|
WO2019114751A1
|
|
Combined use of immune effector cells and radiation therapy for treatment of tumors
|
